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In 2016, President Barack Obama appointed Vice President Joe Biden to lead a “Cancer 
Moonshot” initiative to accelerate and consolidate efforts to prevent, diagnose and treat cancer. 
The Cancer Moonshot Task Force delivered its report 1 in October 2016, and laid out its vision 
to transform cancer research and care, and “achieve a decade’s worth of progress in 5 years”. 
Colorectal Cancer (CRC) was prominently featured in the report: Strategic Goal 4 aims to 
advance health programs, policies, and outreach to help Americans reduce their cancer risk, 
strengthen understanding of environmental determinants of cancer, and enhance the cancer 
screening continuum-concepts which are at the core of CRC prevention. Specifically, the report 
focuses on the expansion of CRC screening in the US, the removal of insurance barriers, and 
recognizes the National Colorectal Cancer Roundtable’s “80% by 2018” initiative 2 (to increase 
CRC screening rates of eligible adults to 80 percent by 2018) as a driving force for state-and 
local-level initiatives to increase CRC screening.       
CRC is a quintessential example of a “screenable” disease 3: It is common and in 
general has a long latency period, early detection can decrease mortality, accurate screening 
modalities and effective treatment options are available, resources are available to screen and 
to provide diagnostic tests in those with positive screening, screening is cost-effective, and 
modalities to screen are accepted by patients and providers. It should also be reemphasized 
that a fundamental attribute of CRC, and one which distinguishes it from other cancers for which 
screening is recommended and widely practiced, is that it is amenable to primary prevention. 
Fletcher and colleagues 4 remind us that prevention is “the act of keeping from happening”, and 
outline the levels of prevention based on timing during disease course: primary prevention 
keeps the disease from occurring at all, by removing its causes and controlling risk factors; 
secondary prevention detects disease early at the asymptomatic stage and when treatment can 
halt progression; tertiary prevention is focused on reduction of complications after disease has 
become clinically evident. Screening for CRC is, to a certain extent, secondary prevention: 
CRC-related mortality is related directly to disease stage at diagnosis; thus, early detection 
identifies at-risk patients before symptoms occur and increases the chances of a favorable 
outcome. Unlike other cancers though, for which early detection (secondary prevention) is the 
only option, screening for CRC relies to a great extent on primary prevention, predominantly 
through the detection and removal of precancerous colorectal polyps. This concept is not new: 
in the 1960s, Gilbertsen 5 suggested that CRC could be a preventable malignancy through 
polypectomy, before the Vogelstein model 6 provided the biologic framework (adenoma to 
carcinoma sequence with long latency) supporting the rationale for more widespread screening.  
CRC screening with current modalities has been shown to decrease cancer occurrence and 
death, and concrete benefits of screening are discernible at the population level: a recent large 
German population-based study 7 showed that cancers detected by screening colonoscopy had 
a lower stage than those diagnosed by colonoscopy in patients with symptoms; the magnitude 
of stage shift was comparable to patients undergoing screening by fecal occult blood testing.  
Where do we stand globally with regards to CRC incidence and mortality? In the US, 
there have been significant long-term declines in overall CRC rates since a peak in the mid-
1980s, and the declines have been more pronounced for those 65 years or older 8. There has 
been vigorous debate 9 regarding the mechanisms driving these downward trends, with some 
attributing the benefit primarily to mass screening, and others to improved risk factors. There is 
a reasonable rationale for both sides of the argument. The observed declines started before 
widespread screening for CRC, and the timing of decreased mortality at the population level is 
not consistent with an effect of screening9, because of the significant time lag (up to a decade) 
between receipt of screening and measurable impact on CRC death rates 10,11 coupled with the 
relatively slow uptake of screening in clinical practice 9. On the other hand, the more recent 
accelerated declines of proximal colon cancer are more plausibly driven by increased use of 
screening colonoscopy and polypectomy, and CRC incidence and mortality have increased in 
persons younger than 50 years, for whom screening is not routinely recommended. Similarly, 
the “risk factor” hypothesis cannot explain the whole picture. A lot has been written about the 
nefarious effects of the Western lifestyle, and the associations between obesity, the metabolic 
syndrome and its components, lack of physical activity, cigarette smoking, and the risk of 
colorectal neoplasia. Disentangling the effect of these factors on CRC risk at a population level 
is more complex than that of screening: while screening is a defined event which can be 
isolated in time, the lifestyle risk factors interact with one another, are influenced by individual 
predisposing genetic and other factors (such as aspirin/NSAID and calcium use), and exert their 
effect over many years. In addition, some of these factors would be expected to influence CRC 
risk in opposite directions; for example, increasing rates of obesity versus decreasing 
prevalence of cigarette smoking. Screening is likely driving the decline in CRC incidence to a 
greater extent than that of CRC mortality, because CRC-related deaths are also affected by 
earlier detection of symptomatic disease, and improvements in cancer therapy. However, 
ascribing the decreasing CRC rates primarily to screening or improved risk factors 
oversimplifies the issue, as it is likely that both are contributory, albeit to a different extent 
depending on time frame.  
Outside the US, the CRC landscape is less than encouraging. The GLOBOCAN 2012 
data 12 depict wide geographical variation in incidence, with rates varying ten-fold in both sexes 
worldwide (highest estimated rates in Australia/New Zealand and lowest in Western Africa). 
Nearly 55% of the cases occur in more developed regions, while more CRC-related deaths 
(52% of the total) occur in less developed regions, reflecting the impact of delayed diagnosis 
and decreased access to modern therapeutic options. Contrary to the US trends, worldwide, 
CRC incidence has increased by more than 30% between 2008 and 2013 13. 
Two compelling studies in this month’s issue of Clinical Gastroenterology and 
Hepatology provide a more global perspective on the current and projected burden of CRC, and 
offer insight into epidemiological trends. In the first study, Murphy and colleagues [CGH citation] 
determined the US age-standardized incidence of CRC from 1975 through 2013, using the 
population-based Surveillance, Epidemiology, and End Results program of cancer registries. 
CRC incidence peaked during 1980-89, with a subsequent decline beginning around 1990. The 
declines in incidence between 1980-84 and 2010-13 were limited to the screening-age 
population, and were more pronounced for whites (40%) than for blacks (26%). In persons aged 
20-49 years, CRC incidence increased by 37% between 1990-94 and 2010-13 and was similar 
for whites and blacks. The study also reported that left-sided CRC incidence began to decrease 
much earlier (in the mid-1980s) than that of right-sided cancer (starting in 2000); this is 
consistent with temporal trends of CRC screening modality use in the US, with colonoscopy 
dominating the field in later years. These data provide a compelling argument to support the 
notion that widespread screening is responsible for declining CRC incidence, because it is 
biologically implausible that the same CRC risk factors would exert opposite effects in 
screening-eligible persons versus those younger than 50. The study cannot draw definitive 
conclusions regarding causality, and it has limitations inherent to registry research: CRC risk 
factors such as cigarette smoking, obesity, aspirin/NSAID use, personal and family history of 
polyps or CRC, inflammatory bowel disease, or Lynch syndrome are not accounted for. 
Nevertheless, the findings mirror those of a recent study from Germany14: after decades of 
steady rise, CRC incidence and mortality have begun to decrease, within 10 years after the 
addition of screening colonoscopy to the German national cancer screening program for adults 
≥ 55 years old. The second study, by Tsoi and colleagues [CGH citation], utilized cancer 
incidence data and population statistics from the International Agency for Research on Cancer 
to project CRC rates in persons 65 years or older in selected countries through 2030, taking into 
account changing population age structures and national income levels. The US was the only 
country with projected declines in CRC incidence, from 227.7/100,000 in 2015 to 190.7/100,000 
in 2030, while the UK and Sweden were projected to experience modest relative increases 
(about 5%) in CRC incidence over the same time frame. Conversely, incidence projections for 
other developed regions such as Japan and Hong Kong and those from developing regions 
such as Croatia, Costa Rica, and Shanghai-China, predicted significant relative increases 
between 2015 and 2030, ranging from 18.5% to 60.5%. Limitations of this study are that the 
data required for the analysis restricted the selection of registries, raising concerns about 
generalizability and representativeness, and that long-term projections are subject to uncertainty 
and multiple possible confounding factors. Nevertheless, it is remarkable that of the selected 
countries, only the US had predicted long-term decline in CRC incidence, bucking global trends-
including those of other developed nations with sophisticated health care systems.  
Given the expanding evidence, it is reasonable to postulate that intensified CRC 
screening efforts could be the primary reason for declining CRC incidence in the US, particularly 
in more recent years. The 80% by 2018 campaign depends on grassroots initiatives, as it 
engages stakeholders including health care providers, health systems, communities, 
businesses, community health centers, state and local government, and cancer survivors, to 
support CRC prevention. The multi-tiered strategies emphasize both risk factor education and 
reduction, and actual screening. Why not build and support similar models beyond the borders 
of the US, under the auspices of the United Nations? We have multiple precedents of 
successful international collaborative efforts to combat and even eradicate communicable 
diseases; why not turn global attention and collaboration to a preventable cancer, one which is 
expected to claim millions of lives over the next 15 years? A global colorectal cancer moonshot 
is needed. 
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